Compulsory vaccination against terrorist attack is unjustified

The compulsory use of vaccines to prevent the effects of a bioterrorist attack seems to be based on an unproved threat, according to an editorial in this week's BMJ.

In 1997 the United States began a compulsory anthrax vaccination programme for military personnel. In 2002, a similar programme also involving civilians, was started against smallpox. Yet these programmes rely on old vaccines for which relatively few data exist, writes Tom Jefferson.

For instance, no large scale trial of the US anthrax vaccine (AVA) has ever been conducted, and trials of the current smallpox vaccine have recently been halted because of safety concerns. Despite this, the website of the United States anthrax vaccine immunisation programme claims proved protection against inhalation anthrax, says the author. Newer vaccines are currently being developed but are a long way from field testing.

"Although field trials are expensive and complex, investment in evaluation and in better and safer vaccines surely must be a requisite to have credible compulsory immunisation programmes involving huge numbers of adults of reproductive age," adds the author. "Until such time, the choice of whether to be vaccinated or not should be left to the individual."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Pfizer-BioNTech vaccine provides strong protection against MIS-C in children aged 5–17